Success Story: Advancing Precision Oncology Through Immunotherapy and Epigenetics: NIW Approval in Molecular and Cellular Biochemistry
Client’s Testimonial:
"I had a very positive experience working with North America Immigration Law Group on my I-140 petition, which was successfully approved. The team was thorough and organized throughout the process, and I especially appreciated how responsive they were whenever I had questions or needed clarification. They made sure my petition was well prepared and guided me through each step without making the process feel overwhelming. I’m very grateful for their work and for the successful outcome, and I would happily recommend them to others going through the immigration process."
On July 20th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Associate in the Field of Molecular and Cellular Biochemistry (Approval Notice).
General Field: Biochemistry
Position at the Time of Case Filing: Postdoctoral Associate
Approval Notice Date: July 20th, 2026
Processing Time: 10 months, 8 days (Premium Processing Upgrade Requested)
Case Summary:
The client’s I-140 National Interest Waiver (NIW) petition was approved based on research in the field of molecular and cellular biochemistry. The client’s work focuses on developing innovative cancer treatment strategies by investigating how immunotherapy can be combined with emerging epigenetic therapies while identifying predictive biomarkers that help determine which patients are most likely to benefit from treatment. This research aims to improve treatment efficacy and clinical outcomes in cancer care, an area that addresses pressing challenges in public health and biomedical science. At the time of filing, the client was conducting research in this field while continuing to investigate the molecular mechanisms underlying cancer development and therapeutic response.
North America Immigration Law Group (Chen Immigration Law Associates) demonstrated that the client’s work carried significance well beyond individual research projects. We explained that the client’s research contributed to the broader advancement of precision oncology by improving the understanding of cancer biology, therapeutic resistance, and biomarker-guided treatment strategies. The petition also highlighted that the client’s research had attracted support from major funding sources, including the National Science Foundation, the National Institute of Environmental Health Sciences, the National Cancer Institute, and the National Institutes of Health, reflecting that the research addressed priorities recognized by leading U.S. research agencies. Rather than relying on future potential alone, we connected the client’s ongoing work to national efforts to improve cancer treatment and patient outcomes.
To establish that the client was well positioned to continue advancing this important area of research, we presented evidence of sustained scholarly achievement and professional recognition. The client earned a Ph.D. in biochemistry and had authored 6 peer-reviewed journal articles (including 2 first-authored publications), 3 conference abstracts (2 first-authored), 2 preprints (1 first-authored), and 2 book chapters (1 first-authored). The client’s research had received 31 citations, and the client had completed at least 21 peer reviews for scientific journals. Rather than presenting these metrics as independently sufficient, we explained how an adjudicator would likely view them collectively as evidence that other researchers had relied upon the client’s findings and that journal editors had recognized the client’s expertise by entrusting the evaluation of scholarly work to the client.
The petition was further strengthened by four recommendation letters submitted by established experts in the field. These letters explained how the client’s research advanced the understanding of cancer biology, epigenetic regulation, and next-generation therapeutic strategies while supporting the conclusion that the client was well positioned to continue contributing to this nationally important area of research. One expert noted:
“She has transformed how scientists understand and target transcriptional vulnerabilities, a shift that is essential for improving patient outcomes and sustaining America’s leadership in biomedical innovation.”
Together with the client’s publication record, citation history, peer-review service, and research funding, these expert evaluations helped demonstrate both the quality and broader influence of the client’s work. USCIS ultimately approved the National Interest Waiver petition after concluding that the evidence established the national importance of the client’s research and the client’s ability to continue advancing innovative cancer treatment strategies in the United States.